Treatment options for TNBC

The biggest distinction in treatment is between early-stage TNBC (still confined to the breast and possibly nearby lymph nodes) and metastatic TNBC (spread to other parts of the body, most often the lungs, liver, bones, or brain). The same drug classes appear in both settings but the goals, sequencing, and intensity differ.

Drug therapy itself comes in several forms. For most of the history of TNBC treatment it was almost entirely cytotoxic chemotherapy. Since 2018 three new classes have changed the picture in specific situations: immune checkpoint inhibitors, antibody-drug conjugates (ADCs), and PARP inhibitors. None of these has replaced chemotherapy — they are added to it, or used after it, in patients whose tumor or genetics make them eligible.

Early-stage TNBC

For most patients with stage II or III TNBC (and increasingly some stage I tumors larger than 1–2 cm or with lymph-node involvement), the standard sequence is:

1. Chemotherapy first, before surgery (called neoadjuvant therapy). This shrinks the tumor and lets the medical team see how the cancer responds to chemo while it is still in the body.
2. Surgery to remove what remains — either lumpectomy (breast-conserving surgery) or mastectomy, depending on tumor location, size, and patient preference.
3. Radiation, usually to the breast and sometimes to nearby lymph nodes.
4. More drug therapy after surgery in some cases — details below.

The pre-surgery chemotherapy regimen

Since 2021, the standard regimen for higher-risk early TNBC has combined chemotherapy with pembrolizumab (Keytruda), an immune checkpoint inhibitor. The full regimen runs about six months: a first phase of pembrolizumab plus paclitaxel and carboplatin, then a second phase of pembrolizumab plus an anthracycline (doxorubicin or epirubicin) and cyclophosphamide. The trial that established this combination (known as KEYNOTE-522) showed substantially better long-term outcomes than chemotherapy alone.

The single most important thing the team looks for at surgery is whether the cancer has been completely eliminated — no residual cancer cells found in the breast or lymph nodes when the surgical specimen is examined. This is called pathologic complete response, or pCR. Patients who achieve pCR have substantially better long-term outcomes than those with residual cancer.

Roughly 60–65% of patients on the pembrolizumab + chemotherapy regimen achieve pCR, compared with around 50% on chemotherapy alone.

After surgery

If pCR was achieved: pembrolizumab is typically continued for about nine months total (counting the pre-surgery doses), but no further chemotherapy is given.

If residual cancer was found at surgery: additional treatment depends on tumor characteristics and prior therapy.

• Capecitabine, an oral chemotherapy taken for about six months, has been shown to improve outcomes in patients with residual TNBC after standard neoadjuvant chemo (established by the CREATE-X trial). It is often offered after the pre-surgery pembrolizumab + chemo regimen as well, though the evidence in that specific setting is still evolving.
• For patients carrying a germline BRCA1 or BRCA2 mutation, an oral PARP inhibitor (olaparib) for one year may be added, based on the OlympiA trial — which showed a meaningful survival benefit in this group.

Radiation

Radiation after lumpectomy is standard. Radiation after mastectomy depends on tumor size, lymph-node involvement, and surgical margins; the decision is made jointly by the surgical, medical, and radiation oncology teams. Modern hypofractionated regimens (fewer, larger doses over 3–4 weeks) are now common and have similar outcomes to older 5–6-week schedules with fewer side effects.

Metastatic TNBC

When TNBC has spread beyond the breast and regional lymph nodes, treatment shifts from a curative goal to controlling the cancer for as long as possible while preserving quality of life. The plan is built sequentially — when one line of therapy stops working, the team moves to the next.

First-line therapy

The first systemic treatment for metastatic TNBC depends on two test results:

• If the cancer expresses PD-L1 — a protein measured on a biopsy specimen using a test that produces a “Combined Positive Score” or CPS, with a threshold of CPS ≥ 10 — pembrolizumab plus chemotherapy is often the first choice. This was established by the KEYNOTE-355 trial.
• If the patient has a germline BRCA1 or BRCA2 mutation found on genetic testing, a PARP inhibitor (olaparib or talazoparib) is an option, sometimes used before chemotherapy depending on how fast the disease is moving.
• Otherwise, chemotherapy alone is the starting point — typically a single-agent regimen chosen for tolerability rather than maximum cell-kill, since metastatic treatment is given over months to years.

After first-line

When the first treatment stops working, several options are available, each chosen based on what the cancer cells look like and what has been tried before:

• Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate that binds to Trop-2, a protein on the surface of most TNBC cells, and delivers a chemotherapy payload directly into them. The ASCENT trial showed it roughly doubled progression-free survival and meaningfully extended overall survival compared with single-agent chemotherapy in patients who had received at least two prior lines of therapy for metastatic disease.
• Trastuzumab deruxtecan (Enhertu) is another antibody-drug conjugate, originally developed for HER2-positive cancers but now also used in tumors with HER2-low expression — meaning the cells show some HER2 (IHC 1+ or 2+ without gene amplification) but not enough to be classified as HER2-positive. About half of historically TNBC tumors fall into the HER2-low category under the new definition. The DESTINY-Breast04 trial established this option after at least one prior line of chemotherapy for metastatic disease.
• PARP inhibitors (olaparib, talazoparib) for patients with germline BRCA1/2 mutations who have not received them already.
• Single-agent chemotherapy — capecitabine, eribulin, vinorelbine, gemcitabine, carboplatin, and others — used in sequence as the cancer progresses. Choice is driven by prior exposure, side-effect profile, and organ function.

The order in which these are used depends on prior treatments, side-effect tolerance, organ function, and patient preference. Decisions are made conversation by conversation as the situation evolves; they are not set in stone at the start.

Clinical trials

For both early-stage and metastatic TNBC, clinical trials are worth asking about at every decision point. TNBC is one of the most actively-researched breast cancer subtypes, and several promising drug classes — next-generation antibody-drug conjugates, novel immunotherapy combinations, and targeted agents for specific molecular subtypes (such as androgen-receptor antagonists for the LAR subtype) — are currently only available through trials.

ClinicalTrials.gov lists open studies; a treating oncologist can help identify trials a patient may be eligible for, and major cancer centers usually have a research nurse or trial-navigator team that handles enrollment logistics.

Side effects, broadly

Most TNBC treatments have meaningful side effects. The most common ones to expect, depending on regimen:

• Chemotherapy — fatigue, hair loss, low blood counts (which raise infection risk), nausea, and sometimes nerve damage (peripheral neuropathy) from taxanes or platinums. Most resolve within months of finishing treatment, though neuropathy can persist longer.
• Pembrolizumab and other immune checkpoint inhibitors — fatigue, skin reactions, and immune-related side effects that can affect the thyroid, adrenals, lungs, liver, or colon. These are usually manageable when caught early but require regular monitoring throughout treatment and for some time afterward.
• Sacituzumab govitecan — diarrhea (sometimes severe), hair loss, low neutrophil counts, fatigue.
• Trastuzumab deruxtecan — nausea, fatigue, low blood counts, and a less common but serious lung side effect (interstitial lung disease) that requires close monitoring with imaging.
• PARP inhibitors — fatigue, nausea, and lower blood counts.

Side-effect management is a substantial part of oncology care. Supportive medications, dose adjustments, and treatment breaks are routine and should be discussed openly with the care team rather than tolerated silently — reporting symptoms early usually makes them easier to manage and avoids more serious complications.

What this page does not cover

A few important areas that have their own pages or that should be discussed individually with the care team:

• Fertility preservation for patients of childbearing age — should be raised before chemotherapy starts.
• Genetic counseling and testing for inherited BRCA1/2 and other mutations — affects both the patient’s treatment options and their family members’ screening.
• Brain metastasis management, which has its own treatment paradigms.
• Palliative and supportive care, which is increasingly recognized as valuable from diagnosis onward, not only at the end of life.

Last reviewed: 2026-05-30. This page is information only, not medical advice. Treatment decisions are personal and depend on factors specific to each patient; always discuss them with a qualified oncology team. Treatments listed here are those approved or in standard use as of the date above; the field is moving quickly and new options may have become available since.